Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.

ABSTRACT:

Background

The antifibrotics pirfenidone and nintedanib are both approved for the treatment of idiopathic pulmonary fibrosis (IPF) by regulatory agencies and are recommended by health technology assessment bodies. Other treatments such as N-acetylcysteine are used in clinical practice but have not received regulatory approval. No head-to-head trials have been conducted to directly compare the efficacy of these therapies in IPF.

Objective

To compare the efficacy of treatments for IPF.

Methods

A systematic review was conducted up to April 2015. Phase II/III randomized controlled trials in adults with IPF were eligible. A Bayesian network meta-analysis (NMA) was used to compare pirfenidone, nintedanib, and N-acetylcysteine with respect to forced vital capacity (FVC) and

SUBMITTER: Fleetwood K 

PROVIDER: S-EPMC10410677 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature